WHO removes TB and malaria drug APIs made by Anuh Pharma from approved list

By Gareth Macdonald contact

- Last updated on GMT

WHO World Health Organization Headquarters in Geneva, Switzerland (iStock/mseidelch)
WHO World Health Organization Headquarters in Geneva, Switzerland (iStock/mseidelch)

Related tags: Pharmacology, Pharmaceutical drug

The WHO has removed two APIs supplied by Anuh Pharma from its list of prequalified ingredients and announced plans to inspect the firm’s facility in Boisar, India.

The World Health Organisation​ (WHO) announced the suspension yesterday, explaining that the move follows criticism​ of operations at the site by French regulator ANSM last month and the subsequent withdrawal of its GMP certificate.

The WHO said: “In the absence of current EU GMP certification, an acceptable standard of GMP can no longer be presumed at this [Boisar] facility.

WHOAPI-158 and WHOAPI-234 will be removed from the WHO List of prequalified APIs until such time as WHO PQT can verify that an acceptable level of GMP is present at the manufacturing site​.”

The APIs in question are pyrazinamide, which is used in tuberculosis drugs, and sulfadoxine, which is used in treatments for malaria.

The WHO told drug formulators to stop sourcing either ingredient from Anuh and to analyse any batches they have already purchased.

Anuh Pharma – which confirmed the suspension in a Bombay Stock Exchange (BSE) filing​ – has asked the WHO to re-inspect the facility.

ANSM criticism

Anuh facility processes APIs supplied by other manufacturers and supplies them to pharmaceutical producers.

ANSM inspectors who visited in February observed 24 deficiencies from good manufacturing practices (GMP) standards according to a report published on EudraGMP​ in March.

The major deviation was Anuh’s failure to pass details of its suppliers on to customers to which it sold processed active pharmaceutical ingredients (API).

The ANSM team also reported that azithromycin supplied to Europe labelled as being manufactured by Anuh was actually made by a non-compliant Chinese supplier called Hebei Dongfeng Pharmaceutical.

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-May-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more